Alyeska Investment Group L.P. trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 72.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,416 shares of the biotechnology company's stock after selling 112,584 shares during the quarter. Alyeska Investment Group L.P. owned about 0.07% of Ascendis Pharma A/S worth $6,611,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of ASND. Balyasny Asset Management L.P. acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter worth $2,123,000. Janus Henderson Group PLC raised its stake in Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after purchasing an additional 193,688 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the 4th quarter valued at $28,000. Tema Etfs LLC bought a new stake in Ascendis Pharma A/S in the 4th quarter valued at $2,621,000. Finally, Soleus Capital Management L.P. bought a new stake in Ascendis Pharma A/S in the 4th quarter valued at $19,824,000.
Wall Street Analysts Forecast Growth
ASND has been the topic of several analyst reports. Cantor Fitzgerald boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Oppenheimer reissued an "outperform" rating and issued a $224.00 price target (up previously from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Cowen reissued a "buy" rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Wedbush boosted their price target on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $244.36.
View Our Latest Analysis on ASND
Ascendis Pharma A/S Price Performance
Shares of ASND traded down $0.69 during trading hours on Monday, hitting $205.22. The stock had a trading volume of 608,323 shares, compared to its average volume of 432,747. The company's fifty day moving average is $183.33 and its two-hundred day moving average is $168.42. The stock has a market capitalization of $12.56 billion, a price-to-earnings ratio of -39.77 and a beta of 0.39. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $208.16.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. Equities analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.
Ascendis Pharma A/S Company Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
